B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
NCT04931160 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2023-04-13
Summary
The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary Sjogren syndrome)
Conditions
- Sjogren's Syndrome
Interventions
- OTHER
-
Blood, fluid, sells and urine samples
Blood, fluid, sells and urine samples will be collected.
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Principal Investigators
-
Valérie Devauchelle · CHRU Brest
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-10
- Primary Completion
- 2035-02-10
- Completion
- 2035-02-10
Countries
- France
Study Locations
More Related Trials
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
NCT02890121 ·Status: COMPLETED
-
Tolerance and Efficacy of Rituximab in Sjogren's Disease
NCT00740948 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
NCT02890134 ·Status: COMPLETED
-
Lymphocyte Sub-populations and Auto Immune Diseases
NCT03901664 ·Status: COMPLETED
-
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
NCT05689463 ·Status: RECRUITING ·Phase: NA
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control
NCT02890147 ·Status: COMPLETED
-
Ro60 Expression in Macrophages in Sjogren's Disease
NCT06324968 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
NCT06551389 ·Status: RECRUITING
-
Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
NCT01008982 ·Status: COMPLETED ·Phase: PHASE2
-
The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice
NCT04558203 ·Status: COMPLETED
-
Prevalence of Pre-clinical Sjögren Disease and Other Immune Disturbances in Subjects With Autoimmune Thyroiditis Disease
NCT06324578 ·Status: RECRUITING
-
Study of Iguratimod in Sjögren's Syndrome
NCT03023592 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Molecular Diagnosis of Systemic Autoinflammatory Diseases
NCT05364294 ·Status: RECRUITING
-
Anti-nucleosome B Lymphocytes in Lupus
NCT01889654 ·Status: TERMINATED
-
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
NCT02891213 ·Status: UNKNOWN
-
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
NCT05383339 ·Status: RECRUITING
-
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
NCT06647069 ·Status: RECRUITING ·Phase: PHASE1
-
New Clinical End-points in Patients With Primary Sjögren's Syndrome
NCT05113004 ·Status: RECRUITING ·Phase: PHASE2
-
Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
NCT01534403 ·Status: COMPLETED ·Phase: PHASE2
-
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
NCT06491602 ·Status: RECRUITING
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation
NCT04320680 ·Status: RECRUITING ·Phase: NA